Alzheimer's disease

@article{Ballard2011AlzheimersD,
  title={Alzheimer's disease},
  author={Clive G Ballard and Serge Gauthier and Anne Corbett and Carol Brayne and Dag Aarsland and Emma L. Jones},
  journal={The Lancet},
  year={2011},
  volume={377},
  pages={1019-1031}
}
An estimated 24 million people worldwide have dementia, the majority of whom are thought to have Alzheimer's disease. Thus, Alzheimer's disease represents a major public health concern and has been identified as a research priority. Although there are licensed treatments that can alleviate symptoms of Alzheimer's disease, there is a pressing need to improve our understanding of pathogenesis to enable development of disease-modifying treatments. Methods for improving diagnosis are also moving… Expand
A Meta-Analysis Study on Alzheimer’s Disease
  • Journal of Bioscience & Biomedical Engineering
  • 2021
To gather and assess information on Alzheimer’s disease and its treatment from published studies to depict the overall treatment effect. The metaphysical findings appear to indicate that Alzheimer’sExpand
The Role of Genetics in Advancing Precision Medicine for Alzheimer’s Disease—A Narrative Review
TLDR
Strategies to implement genomics into translational clinical research that will not only improve accuracy of dementia diagnosis, thus enabling more personalized treatment strategies, but may also speed up the discovery of novel drugs and interventions are outlined. Expand
Overview of Alzheimer's and Parkinson's diseases and the role of protein aggregation in these neurodegenerative diseases
TLDR
This chapter provides an overview of AD and PD, and it discusses current theories of the relationship between protein aggregation and neurodegeneration. Expand
A review of β-amyloid neuroimaging in Alzheimer's disease
TLDR
The main efforts of neuroimaging in AD in humans and in mouse models are summarized, with a specific focus on β-amyloid, and the potential of new applications and novel approaches are discussed. Expand
Latest treatment options for Alzheimer’s disease, Parkinson’s disease dementia and dementia with Lewy bodies
TLDR
This review summarises the current understanding of the underlying biology of AD, PDD and DLB and outlines the most recent drug candidates in advanced clinical trials. Expand
Prevention strategies for Alzheimer’s disease
TLDR
Primary prevention studies include studying those subjects with more risk factors for AD, such as older age, those with a positive family history of late onset AD, and those who are ApoE4 positive, designed to increase the probability of developing AD thereby decreasing the sample size or the duration of follow up. Expand
The Epidemiology and Prevention of Alzheimer’s Disease and Projected Burden of Disease
TLDR
International collaboration is necessary to initiate future large-scale dementia prevention studies that are needed to formulate evidence-based preventive measures in cognitive decline and dementia. Expand
State of the Science: Use of Biomarkers and Imaging in Diagnosis and Management of Alzheimer Disease
  • Deirdre Brett Fraller
  • Medicine
  • The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses
  • 2013
TLDR
New techniques able to identify AD in its earliest stages, before the development of the cognitive impairment that allows clinical diagnosis, could enable treatment to begin before pathology is advanced, and discuss how they might be used in the diagnosis and management of AD. Expand
Genetics of Alzheimer's Disease
TLDR
The known genetics of early- and late-onset Alzheimer's disease are reviewed, including APOE, which is a complex disorder with environmental and genetic components leading to disease. Expand
Dementia in Down's syndrome
TLDR
Despite close similarities with late-onset Alzheimer's disease, individuals with Down's syndrome respond differently to treatment, and a targeted approach to drug development is thus necessary. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 111 REFERENCES
Cholesterol as a risk factor for Alzheimer's disease – epidemiological evidence
TLDR
This review aims at presenting current epidemiological data on serum cholesterol levels and dietary fat intake as risk factors for dementia/AD, and at discussing the reasons and significance of contradictions between various studies. Expand
Imaging cerebral atrophy: normal ageing to Alzheimer's disease
TLDR
Serial MRI could track disease progression and detect neurodegenerative diseases earlier to allow prompt and specific treatment, and the amount and pattern of excess atrophy might help to predict the underlying pathological process, allowing specific therapies to be started. Expand
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study
TLDR
The association between pathological CSF and progression to Alzheimer's disease was much stronger than, and independent of, established risk factors including age, sex, education, APOE genotype, and plasma homocysteine. Expand
Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion
TLDR
MRI is already become an indispensable tool in clinical trials in dementia and will be the identification of patients at risk for Alzheimer's disease or with preclinical Alzheimer’s disease. Expand
AddNeuroMed—The European Collaboration for the Discovery of Novel Biomarkers for Alzheimer's Disease
TLDR
The development and design of AddNeuroMed and the progress toward the development of plasma markers show that plasma markers are feasible and animal models are valuable in biomarker research. Expand
Early diagnosis of Alzheimer's disease using cortical thickness: impact of cognitive reserve
TLDR
Using a normalized thickness index-based criterion may help with early diagnosis of Alzheimer's disease at the individual level, especially for highly educated subjects, up to 24 months before clinical criteria for Alzheimer's Disease diagnosis are met. Expand
Research criteria for the diagnosis of Alzheimer's disease: revising the NINCDS–ADRDA criteria
TLDR
These new criteria are centred on a clinical core of early and significant episodic memory impairment and stipulate that there must also be at least one or more abnormal biomarkers among structural MRI, molecular neuroimaging with PET, and cerebrospinal fluid analysis of amyloid beta or tau proteins. Expand
Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade
TLDR
This work proposes a model that relates disease stage to AD biomarkers in which Abeta biomarkers become abnormal first, before neurodegenerative biomarkers and cognitive symptoms, and neurodegnerative biomarker become abnormal later, and correlate with clinical symptom severity. Expand
Recommendations for the diagnosis and management of Alzheimer's disease and other disorders associated with dementia: EFNS guideline
TLDR
This international guideline on dementia covers major aspects of diagnostic evaluation and treatment, with particular emphasis on the type of patient often referred to the specialist physician, and revised the recommendations for clinical diagnosis, blood tests, neuroimaging, electroencephalography, and cerebrospinal fluid analysis. Expand
Cerebral infarcts in patients with autopsy-proven Alzheimer's disease
TLDR
The clinical-neuropathologic correlations in CERAD patients generally confirm those in prior studies, indicating that the presence of cerebral infarction in patients with AD is associated with greater overall severity of clinical dementia and poorer performance on specific tests of language and cognitive function. Expand
...
1
2
3
4
5
...